⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of iQure Pharma Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
iQure Pharma Inc.
↗Princeton, USA
iQure Pharma is a clinical-stage biotechnology company focused on developing novel therapeutics for central nervous system (CNS) disorders. The company's core scientific approach involves restoring glutamate homeostasis by enhancing the function of EAAT2, the brain's primary glutamate transporter, to break the cycle of excitotoxicity that drives neuronal damage.
The company's pipeline is centered on small-molecule positive allosteric modulators of EAAT2. Its lead asset, iQ-007, is currently in clinical development for treatment-resistant epilepsy, with potential applications in other neurodegenerative and neuroinflammatory conditions, including Parkinson's disease, Alzheimer's disease, ALS, and chronic pain.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$2.1M
Investors:Ventura BioMed Investors, OKG Capital, Keiretsu Forum Mid-Atlantic
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule
Active Trials:0
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University of Padova (Research collaboration), Jagiellonian University (Collaboration on iQ-007 development)
COMPETITION
Position:Emerging
Competitors:argenx, Vor Biopharma, Horizon Therapeutics
LEADERSHIP
Key Executives:
Pawel Zolnierczyk - CEO
Henk de Wilde - Chief Development and Operations Officer
LINKS
Website:iqurepharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with iQure Pharma Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.